References
- Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–2189.
- Adcetris.com [Internet]. Seattle, Washington: Seattle Genetics. 2018 [cited 2018 Mar 14]. Available from: http://adcetris.com
- Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888–897.
- Gravanis I, Tzogani K, Hennik P, et al. The European medicines agency review of brentuximab vedotin (adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2016;21:102–109.
- Zhao B, Chen R, O’Connor OA, et al. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol. 2016;82:696–705.
- Fanale M, Whiting N, Forero-Torres A, et al. Treatment strategies to optimise outcomes with Brentuximab vedotin: management of common and rare toxicities. J Targ Ther Ca. 2015;4:36–44.